Zura Bio press release (ZURA): Q3 GAAP EPS of -$0.20 in-line. R&D expenses were $19.5 million for the third quarter of 2026. As of September 30, 2026, Zura had
CryptoAlerta — análise de criptomoedas e mercado em tempo real